Role of microRNAs in Non-Alcoholic Steatohepatitis

被引:22
|
作者
Cheung, Onpan [1 ]
Sanyal, Arun J. [1 ]
机构
[1] Virginia Commonwealth Univ, Div Gastroenterol Hepatol & Nutr, Dept Internal Med, Med Ctr, Richmond, VA 23298 USA
关键词
microRNA; non-alcoholic steatohepatitis; non-alcoholic fatty liver disease; insulin resistance; metabolic syndrome; UNFOLDED PROTEIN RESPONSE; HEPATIC LIPOGENESIS; CARDIOVASCULAR RISK; IN-VIVO; GENE; ACTIVATION; OBESITY; ACID; DYSREGULATION; METABOLISM;
D O I
10.2174/138161210791208866
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is not entirely understood. Recently, the role of microRNA in this liver disease entity and its implication in disease pathogenesis and therapeutic potential has advanced rapidly over the year. While the regulation of miRNA function and its mechanism of actions on translational control of target mRNA expression remain unknown, advances in miRNA research allow identification and biochemical characterization of events that limit protein expression, which is crucial in various forms of human diseases and their subsequent development. It is hoped that further understanding of the role of microRNA in NAFLD will advance potential therapeutics and preventive measures to modify and alter this disease process.
引用
收藏
页码:1952 / 1957
页数:6
相关论文
共 50 条
  • [31] The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement
    Pedro Paulo Caravatto
    Ricardo Cohen
    Current Atherosclerosis Reports, 2017, 19
  • [32] Treatment of non-alcoholic steatohepatitis: role of ursodeoxycholic acid
    Schalm, SW
    von Hoek, B
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 185 - 187
  • [33] Role of ADAMTS5 in non-alcoholic steatohepatitis
    Lijnen, H. R.
    Bauters, D.
    THROMBOSIS RESEARCH, 2018, 164 : S242 - S242
  • [34] Drugs and non-alcoholic steatohepatitis
    Farrell, GC
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 132 - 139
  • [35] Obesity and non-alcoholic steatohepatitis
    García-Monzón, C
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 117 - 123
  • [36] Saroglitazar for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 698 - 698
  • [37] Mechanisms of non-alcoholic steatohepatitis
    McClain, CJ
    Mokshagundam, PL
    Barve, SS
    Song, ZY
    Hill, DB
    Chen, T
    Deaciuc, I
    ALCOHOL, 2004, 34 (01) : 67 - 79
  • [38] Metformin in non-alcoholic steatohepatitis
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Zoli, M
    Melchionda, N
    LANCET, 2001, 358 (9285): : 893 - 894
  • [39] Selonsertib for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 852 - 852
  • [40] Treatment of non-alcoholic steatohepatitis
    Angulo, P
    Lindor, KD
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) : 797 - 810